The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,264.00
Bid: 12,280.00
Ask: 12,282.00
Change: 146.00 (1.20%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: Lower Call; Restaurant Group CEO To Depart

Thu, 14th Feb 2019 07:46

LONDON (Alliance News) - London share prices are set to pull back slightly on Thursday following three consecutive sessions of gains which had been driven by hopes of a trade detente between the US and China.In early company news, AstraZeneca reported an annual product sales rise following a "very strong" fourth quarter, easyJet confirmed it is exploring its options in respect of struggling Italian flag carrier Alitalia, and Restaurant Group's chief executive is to step down for personal reasons, just months after the company closed its GBP357 million acquisition of noodle chain Wagamama. IG says futures indicate the FTSE 100 index of large-caps to open 7.74 points lower at 7,183.10 on Thursday. The FTSE 100 index closed up 57.70 points, or 0.8%, at 7,190.84 on Wednesday, and is currently 1.7% higher for the week."Slow but seemingly steady progress is being made on trade issues and that has been enough to stabilise investor sentiment. Data out of China was also helping the mood," said Jasper Lawler, head of research at London Capital Group.Chinese Vice Premier Liu He met with top US officials in Beijing on Thursday for negotiations to avert a worsening of the countries' trade war, ahead of a US deadline for raising tariffs on Beijing's goods further.Liu met with US Trade Representative Robert Lighthizer and Secretary of the Treasury Steven Mnuchin following talks between lower-level US and Chinese officials earlier in the week.Both sides hope to resolve their dispute over two days of talks ahead of March 1, a deadline earlier set by US President Donald Trump to extend tariffs on Chinese goods.Since July, the US has imposed tariffs of 25% on USD50 billion worth of Chinese goods and 10% on another USD200 billion worth, with China retaliating in a similar manner. The US now stands to raise the 10% tariff to 25%.Meanwhile, data showed Chinese exports grew 9.1% in January from a year earlier, surprising economists who had expected exports to shrink for the second month in a row. Imports declined 1.5%.In other data overnight, Japan's economy expanded at an annualized rate of 1.4% in the October-to-December period, marking the first growth in two quarters, the government said Thursday.The preliminary reading was slightly better than the 1.2% growth forecast by analysts surveyed by the Nikkei business daily.In Asia on Thursday, the Japanese Nikkei 225 index closed flat. In China, the Shanghai Composite closed down 0.1%, while the Hang Seng index in Hong Kong is 0.3% lower.In the US on Wednesday, Wall Street ended higher, with the Dow Jones Industrial Average ending up 0.5%, the S&P 500 up 0.3% and Nasdaq Composite edging up 0.1%.To come in the economic events calendar on Thursday has a GDP reading from the eurozone at 1000 GMT. There are also US producer prices and retail sales figures at 1330 GMT.In company news, AstraZeneca reported growth in product sales as its annual performance was boosted by a "very strong" final quarter. Product sales in 2018 rose 4% at both actual and constant exchange rates year-on-year to USD21.04 billion, up 5% in the fourth quarter alone. Total revenue, however, fell 2% to USD22.09 billion, and operating profit was down 8% to USD3.39 billion. "Closing the year with another strong quarter, our performance confirmed that AstraZeneca has returned to growth. Our new medicines performed particularly well across the therapy areas and the Emerging Markets business went from strength to strength. 2019 will be a year of focus on continued pipeline delivery and flawless commercial execution," said Chief Executive Pascal Soriot.For 2019, the company expects a high single-digit percentage increase at constant currencies in product sales, while core earnings per share is expected in a range of USD3.50 to USD3.70. Core EPS in 2018 fell 19% year-on-year at constant exchange rates to USD3.46.Core operating profit is anticipated to increase, ahead of product sales, by a mid-teens percentage. For 2018, core operating profit fell 17% at constant exchange rates to USD5.67 billion.Astra will pay a USD2.80 dividend for the year, unchanged from 2017.Micro Focus International posted a fall in annual revenue as it believed the most "disruptive" issues related to its HPE Software integration have now passed.Pro-forma revenue for the twelve months to October 31 fell 5.3% year-on-year to USD4.06 billion, favourable compared to guidance of between a 6% to 9% fall. Adjusted earnings before interest, taxes, depreciation and amortisation rose 9.2% to USD1.53 billion.On a statutory basis, revenue for the 18 months to the end of October - Micro Focus changed its year-end date following the acquisition of the HPE Software business - was USD4.75 billion, and the company posted a pretax profit of USD34.1 million.For the twelve months to the end of October, the company posted a loss of USD78.5 million. For the financial year ended April 30, 2017, Micro Focus generated a profit of USD131.5 million."The path to our current position has been a complex and difficult one over the last year as we worked to integrate the Hewlett Packard Enterprise Software business," commented Chief Executive Stephen Murdoch."Integrations of this scale are always challenging and significant programmes of work are still in progress but we believe the most disruptive issues experienced since completion are now behind us," he added. Looking ahead, the company expects revenue for the recently-commenced financial year to fall between 4% to 6% on last year, with the first quarter performance in line with this guidance. Coca-Cola HBC said it achieved its second year of forex-neutral revenue growth above its target range as it made good progress towards its 2020 margin targets. Volumes for 2018 grew 4.2% to 2.19 billion cases, with net sales revenue up 2.1% to EUR6.66 billion with currency-neutral net sales revenue up 6.0%.The soft drinks bottler generated a pretax profit of EUR610.9 million for the year, compared to EUR564.9 million last year. The company proposed a dividend of EUR0.57, up 5.6% on the year before. "Economic growth in 2019 is forecast to slow down in a number of our markets, which is likely to negatively impact consumer spending in the Established and Developing segments," Coca-Cola HBC said.The company added: "We believe that we are well-placed to withstand these more challenging conditions given our strong marketing programmes, ongoing initiatives in revenue growth management and route to market, together with the new product launches in 2018 which we expect to gain momentum with increased distribution and repeat sales."easyJet confirmed it is in discussions with Ferrovie dello Stato Italiane and Delta Air Lines concerning the formation of a consortium to explore options for the future operations of struggling Italian airline Alitalia. "There is no certainty at this stage that any transaction will proceed and easyJet will provide a further update in due course, if and when appropriate," easyJet said. Rolls-Royce said it has secured an order for Trent 700 engines to power 40 Airbus A330 neo aircraft from Emirates. The FTSE 100-listed engine maker said it will also provide Trent 900 engines for a further 14 Airbus A380s, taking the total Emirates A380 fleet powered by Trent 900 engines to 33 aircraft.Rolls-Royce also noted news that Airbus will end A380 deliveries in 2021."We will provide engines for the 17 remaining Trent 900-powered Airbus A380s to be delivered to customers including Emirates and we will support the whole Trent 900 fleet in service throughout its lifetime," Rolls-Royce said. This comes after Airbus announced it will end production of its flagship A380 superjumbo passenger aircraft, potentially putting UK jobs at risk.The firm said it had made the "painful" decision after struggling to sell the world's largest passenger jet and after Emirates chose to slash its A380 orderbook by around a quarter.Restaurant Group said Chief Executive Andy McCue has decided to leave the company due to "extenuating personal circumstances".McCue is expected to remain in his role while a successor is found, the company said. McCue noted the decision is "untimely" as the board thanked him for "leading [Restaurant Group's] transition into higher growth areas".His departure comes only months after the casual dining group closed its controversial acquisition of pan-Asian restaurant chain Wagamama, with the deal gaining approval from a less than overwhelming 60% of voting shareholders at a general meeting. In the UK, Theresa May is facing the prospect of a fresh Brexit rebellion from hardline Tory MPs in a key Commons vote on the prime minister's EU withdrawal stance.As MPs again vote on Brexit options on Thursday, Eurosceptic Conservatives are threatening to oppose the government's motion.The motion asks the House to reiterate its support for the approach agreed on January 29, when the Commons backed an amendment authorising May to go back to Brussels to renegotiate the controversial Irish backstop.But members of the backbench European Research Group say that it effectively endorses another amendment approved by MPs the same day, which rules out no-deal but is not binding on the government.Labour has tabled an amendment to the government motion requiring May to either put her deal to a Commons vote by February 27 or allow parliament to take control of the process.The Labour leadership is also set to back a proposal from backbencher Yvette Cooper, expected to be debated on February 27, that would require a vote by the middle of March on delaying Brexit.The pound was quoted at USD1.2870 early Thursday, unchanged from late Wednesday.

More News
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.